Recruitment to the PIVOT (Protease Inhibitor monotherapy Versus Ongoing Triple Therapy) trial reaches 300

24 Jun 2014

The PIVOT trial aims to show if taking a drug from one class (Protease Inhibitors) is just as good as taking the standard treatment of 3 classes of drugs, to treat people with HIV in the long term.

To date 44 UK sites are open and recruiting patients into the PIVOT trial. On 29 January 2010, 300 patients had been recruited into the trial. The recruitment target is for 400 patients; we hope the trial will be fully recruited by the end of April this year.

We will soon be recruiting patients from the PIVOT trial into 2 substudies to look at the effect of PI monotherapy on HIV in the Central Nervous System and in Genital Secretions.

For more information, please contact the PIVOT team at pivot@ctu.mrc.ac.uk.